In the above-named article by Vaidya A and Carey RM (J Clin Endocrinol Metab. 2020;105(12); doi: 10.1210/clinem/dgaa606), the following transcriptional error occurred in the published paper:
On page 7 of the original text under the section heading “When to screen,” the sentence “Beyond these critical populations, strong consideration should be given to screening all patients with stage II hypertension (≥.1/90 mm Hg), among whom the prevalence of primary aldosteronism syndrome is substantial” has been corrected to read:
Beyond these critical populations, strong consideration should be given to screening all patients with stage II hypertension (≥140/90 mmHg), among whom the prevalence of primary aldosteronism syndrome is substantial.
The publisher acknowledges this error.